Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Myrbetriq Mirabegron Overactive bladder Withdrawn
Invokana Canagliflozin Diabetes Mellitus, Type 2 Withdrawn
Komboglyze Saxagliptin + metformin Diabetes Mellitus, Type 2 Withdrawn
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting Withdrawn
Humira Adalimumab ulcerative colitis Withdrawn
TBC Darunavir / cobicistat HIV infection Withdrawn
Remsima Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis Withdrawn
Fampyra Fampridine Multiple sclerosis, improve walking disability Withdrawn
Trintellix Vortioxetine Depression, major depressive disorder Withdrawn
Ibrance Palbociclib Withdrawn